Join to View Full Profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Fax+1 507-284-0161
Dr. Geiersbach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Katherine Geiersbach is a molecular pathologist with expertise in genomic testing on solid tumors.
Education & Training
University of Utah HealthFellowship, Molecular Genetic Pathology, 2007 - 2008
University of ColoradoResidency, Pathology-Anatomic and Clinical, 2002 - 2005
Stanford Health CareInternship, Transitional Year, 2001 - 2002- University of Colorado School of Medicine Anschutz Medical CampusClass of 2001
Certifications & Licensure
MN State Medical License 2016 - 2025
UT State Medical License 2007 - 2018
CO State Medical License 2006 - 2009
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Pathology - Molecular Genetic
American Board of Medical Genetics and Genomics Clinical Cytogenetics and Genomics
Publications & Presentations
PubMed
- Charting the Genomic Frontier: 25 Years of Evolution and Future Prospects in Molecular Diagnostics for Solid Tumors.Jaclyn F Hechtman, Brett Baskovich, Amber Fussell, Katherine B Geiersbach, J Bryan Iorgulescu
The Journal of Molecular Diagnostics. 2025-01-01 - 3 citationsNext generation sequencing-based identification of fusion-driven renal neoplasia: A single institution experience.Burak Tekin, Christopher D Hofich, Beth A Pitel, J Kenneth Schoolmeester, Rumeal D Whaley
Human Pathology. 2024-10-01 - A case of diagnostic uncertainty: High-grade melanocytoma versus balloon cell melanoma in a pediatric patient.Serena Shimshak, Olayemi Sokumbi, Ruifeng Guo, Dawn Marie R Davis, Katherine B Geiersbach
Journal of Cutaneous Pathology. 2024-09-01
Journal Articles
- Chromoanasynthesis Is a Common Mechanism That Leads to ERBB2 Amplifications in a Cohort of Early Stage HER2+ Breast Cancer SamplesKatherine B Geiersbach, Mitesh J Borad, Sarah A McLaughlin, BioMed Central
Lectures
- Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists gui...2019 ASCO Annual Meeting - 6/1/2019
- 26th Annual Park City Combined AP/CP Pathology UpdateARUP Laboratories, Park City, Utah - 2/4/2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
